## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: ROQUES1

In re Application of:
Bernard Pierre ROQUES et al.

IA No: PCT/FR2004/002106

IA Filed: August 6, 2004

Appln. No.:

Not yet assigned

For: NOVEL DERIVATIVES OF 4,4'-)
DITHIOBIS-(3-AMINOBUTANE-1...

Atty. Docket: ROQUES1

Conf. No.:

Art Unit:

Washington, D.C.

February 6, 2006

## INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents U.S. Patent and Trademark Office Customer Service Window Randolph Building, Mail Stop Amendment 401 Dulany Street Alexandria, VA 22314

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §\$1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

- [X] 1. This IDS should be considered, in accordance with 37 CFR \$1.97, as it is filed:
- [X] A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.
- [ ] B. before the mailing date of a first office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 CFR §1.114; or

- [ ] C. after (A) and (B) above, but before final rejection or allowance, and Applicant has made the necessary certification (box "i" below) or paid the necessary fee (box "ii" below):
  - [ ] i. Counsel certifies that, upon information and belief, each item of information listed herein either was
    - [ ] (a) first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
    - [ ] (b) not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, not known to any individual designated in 37 CFR \$1.56(c) more than three months prior to the filing of this IDS.
  - [ ] ii. Credit Card Payment Form, PTO-2038, is attached authorizing payment of the fee set forth in 37 CFR \$1.17(p), presently believed to be \$180. If the enclosed payment is incorrect, please charge any additional fees or credit any overpayment to Deposit Account No. 02-4035 of the undersigned.
- [X] 2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form BN/SB/08A/B) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. Other than U.S. patent(s) and/or published U.S. application(s), which 37 CFR §1.98(a)(2)(ii) does not require to be filed unless specifically required by the Office, a copy of each document listed is attached, except as explained below:
- [ ] A. Document(s) \_\_\_\_\_ is/are deemed substantially cumulative to document(s) \_\_\_\_\_, and,

	with 37 CFR \$1.98(c), a copy of each of the c(s) is not enclosed.
[ ] E submitted to th	3. Certain documents were previously cited by or me Office in the following prior application(s), ed upon under 35 U.S.C. 120:
(insert serial	numbers and filing dates of prior applications)
of the forms PT (or their BN for application(s) these documents of record in ac	rifies these documents by attaching hereto copies (0-892, PTO-1449, PTO/SB/08a and/or PTO/SB/08b orm equivalents) from the files of the prior or a fresh BN/SB/08A and/or BN/SB/08B listing and request that they be considered and made cordance with 37 CFR \$1.98(d). Per 37 CFR es of these documents need not be filed in this
[ ] 3. Do	cument(s) is/are not in the English
	accordance with 37 CFR \$1.98(a)(3), Applicant
c	An English translation of each document (or of the pertinent portions thereof), or a copy of an English-language abstract (or claim) is enclosed.
E i w n	For documents, a corresponding English-language patent or published application as included on the accompanying Form BN/SB/08A, with a line drawn in the margin connecting the non-English-language document with its corresponding English-language document.
	A concise explanation of the relevance of document(s) is found in the attached search report (see reply to
	Comment 68 in the preamble to the final rules; .135 OG 13 at 20).
	concise explanation of the relevance of document(s) is set forth as follows:

In re Appln. Of ROQUES1

## 10/567362 IAP9 Rec'd FCMPTO 06 FEB 2005

[ ]	A concise explanation	of the relevance of
	document(s)	can be found on page(s
	of the specif	fication.
[ ]	A concise explanation	of the relevance of
	document(s)	can be found on the
	attached sheet.	

- [X] 4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).
- [X] 5. Other information being provided for the examiner's consideration follows:

International Search Report

6. In accordance with 37 CFR §\$1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK

Attorneys for Applicant(s)

By: Sheridan Neimark

Registration No. 20,520

SN:lmh

624 Ninth Street, N.W., Suite 300

Washington, D.C. 20001-5303

Telephone: (202)628-5197 Facsimile: (202)737-3528

G:\BN\R\RINU\Roques1\Pto\ids.fee.doc

10/567362

## IAPS REC'S PCT/PTO N 6 FEB 20%

Substitute for form 1449A/PTO		Co	Complete if Known			
			Application Number	Not yet assigned		
<b>INFORM</b>	ATION DIS	CLOSUR	Filing Date	Even date herewith		
STATEMENT BY APPLICANT			First Named Inventor	Bernard Pierre ROQUES		
• • • • • • • • • • • • • • • • • • • •			Group Art Unit			
(use as many sheets as necessary)			Examiner Name			
Sheet 1	of	1	Attorney Docket Number	ROQUES1		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Kind Code <sup>2 (IT</sup> known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		us-				
		US-				
		US-				
		US-				
		US-	_			
		US-				
		US-				
		US-				
		US-				
		US-				
		us-				

	FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Number Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages		
Initials*	No.1	known)			or Relevant Figures Appear	-	
		<u> </u>					

		NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
-	AA	Chauvel, Eric, N. et al., "Differential Inhibition of Aminopeptidase A and Aminopeptidase N by New β-Amino Thiols" J. Med. Chem, (1994), Vol. 37, pp. 2950-2957.	
		Chauvel, Eric, N. et al., "Investigation of the Active Site of Aminopeptidase A Using a Series of New Thiol-Containing Inhibitors", J. Med. Chem, (1994), Vol. 37, pp.1339-1346.	
_		Martin, L., et al., "β-Amino-thiols Inhibit the Zinc Metallopeptidase Activity of Tetanus Toxin Light Chain, J. Med. Chem, (1998), Vol. 41, pp. 3450-3460.	-

Examiner		Date		
Signature		Considered		

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \(^1\) Applicant's unique citation designation number (optional). \(^2\) See Kind Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. \(^3\) Enter Office that issued the document, by the two-letter code (MPO Standard ST.3). \(^4\)For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \(^5\) Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \(^6\) Applicant is to place a check mark here if English language Translation is attached.